发布时间
2026/03/25 04:5812 分钟前源站更新
2026/03/25 04:5812 分钟前首次抓取
2026/03/25 04:5812 分钟前发布时间
12 分钟前源站更新
12 分钟前首次抓取
12 分钟前用于追踪这条内容的来源与记录标识。
Source
原始链接
发布时间
2026/03/25 04:5812 分钟前源站更新
2026/03/25 04:5812 分钟前首次抓取
2026/03/25 04:5812 分钟前发布时间
12 分钟前源站更新
12 分钟前首次抓取
12 分钟前用于追踪这条内容的来源与记录标识。
Source
原始链接
California's highest court leans toward Gilead in considering drugmakers' 'duty to innovate'
发布时间
155 天前
2026-05-06 10:03:16 UTC
源站更新
155 天前
2026-05-06 19:22:07 UTC
首次抓取
155 天前
2026-05-06 10:14:56 UTC
加州最高法院在审理吉利德科学公司的上诉时表现出谨慎态度，该案涉及制药商是否负有开发更安全替代药物的“创新义务”。
The California Supreme Court expressed skepticism toward a lawsuit against Gilead Sciences that seeks to establish a "duty to innovate," which would require drugmakers to develop safer alternatives even when current products are deemed safe.
用于追踪这条内容的来源与记录标识。
